Answers are grounded in this paper and cite their sources.
There are still few prospective longitudinal studies of DMT in MS that show long-lasting effects. The data of longitudinal observation for 15 years on a group of 69 MS patients constantly receiving glatiramer acetate (GA) are presented. The increase in relapse rate and EDSS progression were associated in a subgroup of patients with the presence of at least one relapse during the first 5 years of observation. Only total absence of clinical activity, according to NEDA definition, during at least the first 5 years of therapy might be classified as the “optimal” response to GA.
No takes yet. Share an insight, caveat, or question.
A 2016 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: